Clinical trials
Phase 2 Diabetic Neuropathies trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
96 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 2 |
| 2002 | 1 |
| 2003 | 2 |
| 2004 | 2 |
| 2005 | 2 |
| 2006 | 6 |
| 2007 | 10 |
| 2008 | 6 |
| 2009 | 7 |
| 2010 | 3 |
| 2011 | 4 |
| 2012 | 8 |
| 2013 | 3 |
| 2014 | 4 |
| 2015 | 3 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 4 |
| 2019 | 4 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 3 |
| 2024 | 2 |
| 2025 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 66 |
| Terminated | 14 |
| Recruiting | 6 |
| Unknown status | 5 |
| Withdrawn | 5 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Sangamo Therapeutics | 4 |
| AstraZeneca | 3 |
| BioDelivery Sciences International | 3 |
| Pfizer | 3 |
| SK Life Science, Inc. | 3 |
| Takeda | 3 |
| Tris Pharma, Inc. | 3 |
| AbbVie (prior sponsor, Abbott) | 2 |
| Aziende Chimiche Riunite Angelini Francesco S.p.A | 2 |
| Glenmark Pharmaceuticals Ltd. India | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Diabetic Neuropathies | 96 |
| Diabetes Mellitus | 24 |
| Neuralgia | 20 |
| Pain | 20 |
| Diabetes Mellitus, Type 2 | 7 |
| Peripheral Nervous System Diseases | 6 |
| Chronic Pain | 5 |
| Diabetes Mellitus, Type 1 | 5 |
| Agnosia | 4 |
| Diabetes Complications | 4 |
Trials
Showing 1 to 25 of 96. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.